AGFG1 and plasma cell myeloma: Using the small-molecule inhibitor of BTK, LFM-A13, in a SCID-rab model with primary myeloma cells injected into rabbit bones, Bam and co-workers reported a suppressed osteoclast activity, less osteolytic resorption, and a moderate decrease in myeloma growth [31].